



Synonym

HLA-A*0201 | B2M | MAGE-A4 (KVLEHVVRV)

Source

PE-Labeled Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Tetramer Protein(HLP-HP2H3) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & KVLEHVVRV peptide (Accession # [AAA59606.1](#) (HLA-A*02:01) & [P61769-1](#) (B2M) & KVLEHVVRV).
Predicted N-terminus: Gly 25 & Lys

Molecular Characterization

PE-Labeled Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Tetramer Protein is assembled by biotinylated monomer and PE-labeled streptavidin.

Biotinylated Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Complex Protein is produced by co-expression of HLA and B2M loaded with MAGE-A4 peptide. Biotinylated Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

Conjugate

PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm

Endotoxin

Less than 1.0 EU per µg by the LAL method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, 1% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:
• -20°C to -70°C for 12 months in lyophilized state;
• -70°C for 3 months under sterile conditions after reconstitution.

Background

The MAGE A4 antigen is a cancer-testis antigen and is expressed intracellularly in various solid tumor tissues, MAGE A4230-239 peptide (GVYDGREHTV) is a cytotoxic T lymphocyte (CTL) epitope presented by HLA-A2 The Human HLA-A*0201 MAGE-A4 (GVYDGREHTV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and GVYDGREHTV peptide of the MAGE-A4.

Clinical and Translational Updates

